Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.